



Danaher is a global science and technology innovator committed to helping customers solve complex challenges and improving quality of life around the world. Danaher is ranked 162nd on the 2018 Fortune 500 list with trusted brands that hold unparalleled leadership positions in diagnostics, life sciences, dental and environmental and applied solutions. Danaher has more than 30 operating companies, and a globally diverse team of 67,000 associates united by a shared purpose: to help realize life's potential.

Danaher Diagnostics consists of Beckman Coulter, Cepheid, HemoCue, Radiometer, and Leica Biosystems companies which hold strong market share in different hospital segments such as hospital core lab and point of care (see Figure1). Danaher is expanding its product portfolio into decentralized care settings and is targeting those areas where Danaher can have a positive impact on quality of patient care and cost of managing prevalent diseases.

Figure1: Danaher Diagnostics Company Presence within a Hospital Care Setting



Danaher Diagnostics is actively focusing on creating a complete sepsis diagnostic test portfolio (see Figure 2). The aim is to improve sepsis patient outcomes by reducing mortality and length of stay as well as advance antimicrobial stewardship efforts and reduce healthcare costs by identifying sepsis earlier and more accurately.

Figure2: Danaher Diagnostics Sepsis Portfolio

